Company Profile
INmune Bio Stock Price, News & Analysis
- Ticker:
- INMB
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.91 USD (+0.53%)
Close
Last updated: August 6, 2026
37.8M USD
Market cap
Why the stock is moving
The latest monitored company update is “INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress.” The corresponding closing-price reaction is not yet available.
Company overview
Innate-Immune Therapeutics
INmune Bio develops therapies that modify innate immune responses. Its programs span cell therapy, neuroinflammation and cancer biology.
CORDStrom
CORDStrom is an allogeneic umbilical-cord-derived stromal-cell therapy being developed for recessive dystrophic epidermolysis bullosa, a severe inherited skin disorder.
XPro in Alzheimer's Disease
XPro1595 is a selective soluble-TNF inhibitor in clinical development for early Alzheimer's disease. The program is designed to suppress harmful neuroinflammation while preserving beneficial transmembrane-TNF signaling.
INB03 Oncology Program
INB03 applies the same soluble-TNF mechanism to cancer, with preclinical work evaluating whether it can overcome treatment resistance and reduce metastasis in HER2-positive disease.
INKmune
INKmune is a cell-based medicine designed to prime a patient's natural-killer cells into tumor-killing memory-like cells. It is being evaluated in an open-label Phase 1/2 prostate-cancer study.
Future catalysts
UK marketing-authorization submission for CORDStrom around mid-summer 2026.
European Medicines Agency filing for CORDStrom following the UK submission.
FDA BLA submission for CORDStrom in the fourth quarter of 2026.
Recent news
- 01
- 02
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
Source: INmune Bio
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of INmune Bio (INMB)?
INmune Bio (INMB) most recently closed at 1.91 USD, a +0.53% move versus the previous session.
What is the market cap of INmune Bio (INMB)?
INmune Bio currently has a market capitalization of 37.8M USD on BioPharmSignal.
What does INmune Bio do?
Innate-Immune Therapeutics INmune Bio develops therapies that modify innate immune responses. Its programs span cell therapy, neuroinflammation and cancer biology. CORDStrom CORDStrom is an allogeneic umbilical-cord-derived stromal-cell therapy being developed for recessive dystrophic epidermolysis bullosa, a severe inherited skin disorder. XPro in...
On which exchange is INMB stock listed?
INmune Bio (INMB) is associated with NASDAQ, United States, Biopharma.
What is Innate-Immune?
Innate-Immune Therapeutics INmune Bio develops therapies that modify innate immune responses.
Which conditions is INmune Bio targeting with Innate-Immune?
INmune Bio is associated with oncology, cancer therapeutics, inflammatory disease based on its company overview and current catalyst commentary.
How does INmune Bio describe recent progress with Innate-Immune?
UK marketing-authorization submission for CORDStrom around mid-summer 2026. European Medicines Agency filing for CORDStrom following the UK submission. FDA BLA submission for CORDStrom in the fourth quarter of 2026.
What is Therapeutics?
Innate-Immune Therapeutics INmune Bio develops therapies that modify innate immune responses.